This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk07: Good afternoon, ladies and gentlemen. Thank you for attending today's Bio-Rad fourth quarter and full year 2022 earnings resort conference call. My name is Tia and I will be a moderator for today's call. All lines will be muted during the presentation portion of the call with an opportunity for questions and answers at the end. If you would like to ask a question, please press star one on your telephone keypad. I would now like to pass the conference over to your host, Everett Chung with Bio-Rad. Please proceed.
spk06: Thanks, Tia. Good afternoon, everyone, and thank you for joining us today. Today, we will review the fourth quarter and full year 2022 financial results and provide an update on key business trends for Bio-Rad. With me on the call today are Norman Schwartz, our Chief Executive Officer, Alon Daskal, Executive Vice President and Chief Financial Officer, Andy Last, Executive Vice President and Chief Operating Officer, Simon May, President of the Life Science Group, and Dara Wright, President of the Clinical Diagnostics Group. Before we begin our review, I'd like to caution everyone that we will be making forward-looking statements about management's goals, plans and expectations, our future financial performance, and other matters. These statements are based on assumptions and expectations of future events that are subject to risks and uncertainties. Included in these forward-looking statements are commentary regarding the impact of the COVID-19 pandemic on Bio-Rad's results and operations, and steps Bio-Rad is taking in response to the pandemic. Our actual results may differ materially from these plans and expectations, and it is difficult to predict the full extent of potential impact the pandemic could have in the future. You should not place undue reliance on these forward-looking statements, and I encourage you to review our filings with the SEC where we discuss in detail the risk factors in our business. The company does not intend to update any forward looking statements made during the call today. Finally, our remarks will include references to non-GAAP financials, including net income and diluted earnings per share, which are financial measures that are not defined under generally accepted accounting principles. Investors should review the reconciliation of these non-GAAP measures to the comparable GAAP results contained in our earnings release. With that, I'll now turn the call over to Alain Dasco, our CFO.
spk04: Thank you, Ed. Good afternoon, and thank you all for joining us. Before I begin the detailed fourth quarter and full year discussion, I would like to ask Andy Lust, our Chief Operating Officer, to provide an update on BioRed's global operations. Andy?
spk05: Okay. Many thanks, Alain. Good afternoon, everybody. As we entered Q4, we continued our focus on improving our supply chain situation. During the quarter, some supply chain component constraints still persisted for a number of instruments, but overall were less problematic, and our primary focus was on production to meet demand. As a result, we made solid progress on reducing our backlog in the quarter. However, there was a resulting impact on product sales mix, And as expected, we still exit Q4 with an elevated backlog position for both our life science and clinical diagnostic businesses. Inventory levels remain high as we continue to source components to support demand, our manufacturing transition to Singapore, backlog reduction, and better secure supply continuity through the coming year. While still high, logistics costs showed improvements in Q4, although higher cost of materials continued to persist from purchases earlier in the year. Despite the product supply challenges experienced throughout 2022, we have been extremely pleased with the level of customer support and willingness to work through our backlog with us. As anticipated during the quarter, the global effects of COVID on our business continued to diminish, and in particular, COVID-related sales were roughly in line with our expectations. Overall operations within BioRat were back to normal, with the exception of China, where changing government policy from their previous zero-tolerance policy led to a large increase in infection rates, impacting a significant percentage of the country and our employees. This also had a negative impact on demand for our routine diagnostic tests in China. The fourth quarter also displayed continued strong demand trends across our portfolio, and in particular, we were very pleased with strong placements for the recently launched QX600 droplet digital PCR platform. Initial adopters include customers at the cutting edge of oncology research and testing, such as biodesics, a diagnostics company which is developing a minimum residual disease test for Memorial Sloan Kettering Cancer Center on the platform. Also as noted during the fourth quarter, we entered into an exclusive licensing agreement with Nupro to accelerate the development of next generation highly multiplexed digital PCR assays for oncology applications.
spk00: As we enter 2023,
spk05: We have now developed a strong pipeline across multiple customer segments for the QX600 and in conjunction with our portfolio of many thousands of assays, we expect to see continued strong growth of our Droplet Digital PCR portfolio in 2023. Q4 sales of our process chromatography franchise also displayed strong double-digit growth and we are pleased with the continued performance of this business and adoption of the recently launched pre-packed columns, as well as increasing interest in our Nuvia resins for new biological therapeutics and vaccines. Looking toward 2023, overall demand remains strong and we continue to drive disciplined execution of our strategy. While we still have some challenges in supply chain, Our primary activity is now on scaling production to reduce our instrument backlog and meet growing demand, particularly in the clinical diagnostics business. And we anticipate backlog will be normalized in the second half of the year. Also in the back half of the year, we are planning for the introduction of two new platforms from our development pipeline, the QX Continuum and our second-generation single-cell platform. The continuum represents a next-generation droplet digital PCR system with an integrated workflow that's designed to be cost-effective. Our single-cell application targets the large single-cell multi-omic market. With the COVID pandemic largely behind us, we do not anticipate any meaningful COVID-related sales in 2023. In addition, we continue to monitor the Russia and Ukraine war situation and potential for further sanctions and downside. Thank you for your attention, and I will now pass you back to Olaj.
spk04: Thank you, Andy. Now I would like to review the results of the fourth quarter and full year. Net sales for the fourth quarter of 2022 were $730.3 million, which is a 0.3% decline on a reported basis versus $732.8 million in Q4 of 2021. On a currency-neutral basis, the year-over-year revenue growth was 5.8%. As expected, COVID-related sales continued to taper and were about $13 million in the quarter. Year-over-year core revenue, which excludes COVID-related sales, increased 10.6% on a currency-neutral basis. On a geographic basis, we experienced double-digit currency-neutral year-over-year core revenue growth in the Americas and Asia, while Europe posted a more modest increase, primarily reflecting ongoing supply chain constraints for diagnostic products. As Andy mentioned earlier, despite improvements in the supply chain, we estimate that we ended 2022 with an elevated order backlog of approximately $50 million, of which we expect to retain about $30 million. Sales of the Life Science Group in the fourth quarter of 2022 were $359.7 million, compared to $326.6 million in Q4 of 2021, which is an increase of 10.1% on a reported basis and growth of 16.4% on a currency-neutral basis. The underlying life science year-over-year currency-neutral core revenue growth was 28.1% and benefited in part from the reduction of order backlog. The year-over-year growth was primarily driven by droplet digital PCR, process chromatography, and Western blotting. We also saw good growth for our QPCR products, in part driven by the uptake of our new CFX Opus platform. We continued to experience strong initial customer interest and demand for our recently introduced QX600 DDP-CR system, and we expect a more meaningful revenue contribution from this platform in 2023. Process chromatography, which can fluctuate on a quarterly basis, again posted strong double-digit year-over-year growth. Excluding process chromatography sales, the underlying life science business grew 14% on a currency neutral basis versus Q4 of 2021, and was partially offset by lower COVID-related sales. When also excluding COVID-related sales, revenue growth was 27.1% on a currency-neutral basis. On a geographic basis, LifeScience experienced currency-neutral year-over-year core revenue growth across all three regions. Sales of the clinical diagnostics group in the fourth quarter were $369.6 million compared to $404.9 million in Q4 of 2021, which is an 8.7% decline on a reported basis and a 2.9% decline on a currency-neutral basis. Core clinical diagnostics year-over-year revenue, which excludes COVID-related sales, declined 1.9% on a currency-neutral basis. clinical diagnostics group revenue, which was primarily impacted by ongoing supply chain constraints, which delayed instrument placements across multiple platforms and the uptake of associated consumables. On a geographic basis, the diagnostics group year-over-year currency-neutral core revenue grew in the Americas and declined in Europe and in Asia. In addition to supply chain constraints, Asia Pacific sales were also impacted by COVID dynamics in China, resulting in lower volume of routine testing. During the fourth quarter of 2022, we corrected two accounting policies and believe these changes are immaterial to our overall financials. We determined that R&D expenses associated with developing and enhancing our cloud-based capabilities that incurred during the years 2020 through 2022 should have been capitalized. We revised our historical financial statements to reflect this correction, and it will be reflected in our 10-K filing. For full year 2022, the correction was about $5 million, or about 20 basis points headwind to gross margin, and the benefit of about $8 million, or about 30 basis points for operating margin. The benefit for the full year adjusted EBITDA margin is $15 million, or about 50 basis points. By comparison, the 2021 full year gross margin headwind is estimated to be about $3 million, or about 10 basis points, with an operating margin benefit of $11 million, or about 40 basis points, and adjusted EBITDA margin benefit of $15 million, or 50 basis points. In addition, we corrected our policy on the timing of revenue recognition related to certain equipment that requires installation, and we believe that it contributed $5 to $10 million of one-time revenue to the quarter. The reported gross margin for the fourth quarter of 2022 was 54.4% on a GAAP basis and compares to 54.6% in Q4 of 2021. The fourth quarter year-over-year gross margin decline was mainly due to an unfavorable product mix reflecting a higher percentage of instrument sales, lower COVID sales, and higher raw material costs associated with supply chain constraints. Amortization related to prior acquisitions recorded in cost of goods sold was $4.4 million as compared to $4.7 million in Q4 of 2021. SG&A expenses for Q4 of 2022 were $212.2 million, or 29.1% of sales, compared to $224.1 million, or 30.6% in Q4 of 2021. The year-over-year SG&A expenses decreased mainly due to the stronger dollar and normalized employee-related benefits but was partially offset by higher discretionary spend. Total amortization expense related to acquisitions recorded in SG&A for the quarter was $1.7 million versus $1.8 million in Q4 of 2021. Research and development expense in the fourth quarter was $66.2 million or 9.1% of sales compared to $66.9 million or 9.1% of sales in Q4 of 2021 and consistent with our targeted R&D investment. Q4 operating income was $118.7 million, or 16.2% of sales, compared to $108.9 million, or 14.9% of sales in Q4 of 2021. Looking below the operating line, the change in fair market value of equity securities holding which are substantially related to buy rates ownership of Sartorius AG shares, added $979 million of income to the reported results. During the quarter, interest and other income resulted in net other expense of $6.1 million compared to net other income of $7.5 million last year. Q4 of 2022, included a $14.4 million charge associated with an investment internment. Overall, we generated $16.6 million in interest income during the fourth quarter from our cash balance, partially offset by $11.7 million in interest expense related to our 1.2 billion notes. The effective tax rate for the fourth quarter of 2022 was 24.2% compared to 22.8% for the same period in 2021. The effective tax rate reported in Q4 of 2022 was partially affected by an unrealized gain in equity securities, and the tax rate reported in Q4 of 2021 was primarily affected by an unrealized loss in equity securities. Reported net income for the fourth quarter was $828 million, or $27.78 diluted earnings per share, compared to a loss of $1,572,000,000, or a diluted loss per share of $52.54 in Q4 of 2021. This increase from last year is largely related to changes in the valuation of the Sartorius Foldings. Moving on to the non-GAAP results. Looking at the results on a non-GAAP basis, we have excluded certain atypical and unique items that impacted both the gross and operating margins, as well as other income. These items are detailed in the reconciliation table in the press release. Looking at the non-GAAP results for the fourth quarter, in cost of goods sold, we have excluded $4.4 million of amortization of purchased intangibles and a small restructuring benefit. These exclusions moved the gross margin for the fourth quarter of 2022 to a non-GAP gross margin of 54.9% versus 55.2% in Q4 of 2021. Non-GAP SG&A in the fourth quarter of 2022 was 28.5%, versus 30.2% in Q4 of 2021. In SG&A, on a non-GAAP basis, we have excluded amortization of purchased intangibles of $1.7 million, an in vitro diagnostic registration fee in Europe for previously approved products of $2.5 million, acquisition-related benefit of $500,000, and $700,000 of legal expenses as well as restructuring-related expenses. Non-GAAP R&D expense in the fourth quarter of 2022 was 9.1% versus 9.4% in Q4 of 2021. In R&D, on a non-GAAP basis, we have excluded a small restructuring benefit. The cumulative sum of these non-GAAP adjustments result in moving the quarterly operating margin from 16.2% on a GAAP basis to 17.4% on a non-GAAP basis. This non-GAAP operating margin compares to a non-GAAP operating margin of 15.7% in Q4 of 2021. We have also excluded certain items below the operating line which are the increase in value of the Sartorius equity securities and loan receivable of $979 million, a $14.4 million loss associated with an investment impairment, and $1.7 million loss on venture investments. The non-GET effective tax rate for the fourth quarter of 2022 was 28.1%, which is consistent with our full year tax rate guidance compared to 20.4% for the same period in 2021. The higher rate in 2022 was driven by geographical mix of earnings. And finally, non-GAAP net income for the fourth quarter of 2022 was $98.5 million or $3.31 diluted earnings per share compared to $98.5 million or diluted earnings per share of $3.26 in Q4 of 2021. Moving on to the full year results. Net sales for the full year of 2022 were $2,802,000,000, which is a 4.1% decline on a reported basis, as compared with $2,923,000,000 in 2021. On a currency neutral basis, full year 2022 net sales increased by 0.3%. And when also excluding in 2021, a one time $32 million settlement for back royalties from 10X, sales in 2022 grew 1.5% on a currency neutral basis. COVID related sales for the full year were about $109 million, compared to $266 million in 2021. Year-over-year core revenue, which excludes COVID-related sales and the legal settlement, increased 7.2% on a currency-neutral basis. Sales of the Life Science Group for 2022 were $1,347,000,000, excluding the 2021 legal settlement the year-over-year growth was 2.7% on a currency-neutral basis. When excluding COVID-related sales and the 2021 legal settlement, life science year-over-year currency-neutral core revenue growth was 15.2%. The majority of the year-over-year core growth was driven by droplet digital PCR, process chromatography, RQPCR products, and Western blots. On a geographic basis, life science currency-neutral full-year core revenue grew across all three regions. Sales of clinical diagnostics products for 2022 were $1,451,000,000, which is a 0.4% growth on a currency-neutral basis. When excluding COVID-related sales, clinical diagnostic year-over-year currency-neutral Core revenue growth was 1.3%, which was impacted by supply chain constraints. On a geographic basis, clinical diagnostics, currency neutral, full-year core revenue grew in the Americas and Europe, while sales declined in Asia, primarily due to COVID lockdowns in China. As mentioned earlier, the year-ago comparisons for gross operating and adjusted EBITDA margin have been modestly revised due to our adoption of capitalized internal use software accounting. The full year non-GET gross margin was 56.6% compared to 57.2% in 2021. The year-over-year margin decline was driven mainly by product mix, lower COVID sales, higher logistics and expedited freight costs, as well as higher raw material costs. Full-year non-GAAP SG&A expense was $805.4 million, or 28.7% of sales, compared to $824 million, or 28.5% in 2021. The lower SG&A spend benefited from a strong dollar and more normalized employee-related costs, somewhat offset by higher discretionary expenses. Full year non-GAAP R&D was $256.7 million or 9.2% of sales versus $247.6 million or 8.6% in 2021. And full year non-GAAP operating income was 18.7% compared to 20.1% in 2021. largely due to the various impacts of our supply chain constraints during the past year. Lastly, the non-GAAP effective tax rate for the full year of 2022 was 22%, which was consistent with our guidance range and compares to 21.2% in 2021. Moving on to the balance sheet. Total cash and short-term investments at the end of 2022 was $1,796,000,000 compared to $875,000,000 at the end of 2021 and $1,856,000,000 at the end of the third quarter of 2022. The change in cash and short-term investment for the third quarter of 2022 was primarily due to working capital and share repurchases. Inventory at the end of Q4 reached $719.3 million from $685.9 million in the prior quarter. The increase in inventory continues to reflect our supply chain constraints and is mainly due to carrying higher levels of raw materials. As we anticipate further easing in our supply chain constraints in 2023, we would expect to lower inventory levels over the next eight quarters. For the fourth quarter of 2022, net cash generated from operating activities was $79.7 million, which compares to $161.1 million in Q4 of 2021. These decrease mainly reflect changes in working capital. For the full year of 2022, net cash generated from operations was $194.4 million versus $669.5 million in 2021. These decrease also mainly reflect changes in working capital. During the fourth quarter, we purchased 241,000 shares of our stock for a total cost of $91 million, or an average purchase price of approximately $376 per share, as we continue to be opportunistic with our share buyback program. We still have a total of approximately $207 million available under the current board authorized program. Full year share buybacks totaled 497,000 shares for approximately $216 million. In 2021, we purchased about 90,000 shares of our stock for $50 million. Adjusted EBITDA for the fourth quarter of 2022 was 21.4% of sales. The adjusted EBITDA in Q4 of 2021 was 19.5%. Full year adjusted EBITDA including the Sartorius dividend was $667.9 million or about 23.8% compared to 24.6% in 2021. Net capital expenditures for the fourth quarter of 2022 were $34.7 million and full year CapEx spend was $112.6 million. Depreciation and amortization for the fourth quarter was $35.5 million and $137.3 million for the full year. Moving on to the non-GAAP guidance for 2023. While the supply chain constraints have created a more than anticipated challenge during 2022, we believe that it is transitory and does not change our thinking about our 2025 financial outlook. We expect that our backorder dynamics will continue to normalize, and as I mentioned earlier, we assume to recover in 2023 about $30 million of the order backlog from 2022. We are guiding a currency-neutral revenue growth in 2023 to be between 6 and 7%. Starting in 2023, we do not anticipate breaking out COVID-related sales as its contribution becomes immaterial to our overall revenue base. When excluding the 2022 COVID-related sales, we estimate currency-neutral revenue growth in 2023 to be between 10 and 11%. The life science group, year-over-year currency neutral revenue growth, is expected to be between 8% and 9%. When normalizing for 2022 COVID-related sales, we expect to be between 16% and 18% currency neutral year-over-year revenue growth for the life science group. For the diagnostics group, we estimate currency neutral revenue growth of about 5%. as we expect supply chain constraints to normalize in 2023. When excluding COVID-related sales, we expect revenue growth between 5% and 5.5% for the diagnostics group. Due to the elevated order backlog during 2022, we realized about 1% price improvement, which was below the inflationary trends in our overall cost. For 2023, we assume price increase realization between 1.5% and 1.8%, mainly within the life science group. Full year non-GAAP gross margin is projected to be about 57% in the first half of 2023 and improving to 58% towards the end of the year as we cycle through higher material costs embedded in our inventory and we expect our logistics costs to normalize. Full-year non-GAAP operating margin is projected to be approximately 19.5%. We estimate the non-GAAP full-year tax rate to be between 22% and 23%. CAT-X is projected to be approximately $180 million as we plan to complete our ERP implementation in Asia as well as capacity expansion to support our multi-year growth strategy. Finally, full-year adjusted EBITDA margin is expected to be about 25%. And now I'll turn the call over to Norman for a few remarks. Norman?
spk03: So thank you, Ilan. I guess I would say that, you know, after three pandemic-influenced years, it is really encouraging to see signs of returning to a what I think of as a more normalized business environment. As you might imagine, everybody here is really looking forward to putting the challenges of the last few years behind us. And I guess I would add that the muscle building and improvements that we made as a result during this time, I think will continue to be valuable for us going forward. If I think about the macro view a little bit, even though China and Russia you know, as Andy mentioned earlier, continue to be a little bit challenged. It would appear that most of our markets around the world will be strong in 2023, really supported by a kind of a solid funding environment around our targeted market. I think overall, we are certainly pleased with the progress that we're making on our strategic initiatives. And I think it's fair to say we have a robust pipeline of products and development to support our ambitions going forward. So, you know, we're continuing also to evaluate opportunities to add to our portfolio inorganically. So, lots to look forward to.
spk06: Operator, that concludes our prepared remarks and we'll now open the line to take your questions.
spk07: We will now begin the QA session. If you would like to ask a question, please press star followed by one on your touch-down keypad. If for any reason you would like to remove that question, please press star followed by two. Again, to ask a question, press star one. As a reminder, if you are using a speakerphone, please remember to pick up your handset before asking your question. We will pause here briefly to allow questions to generate in queue. The first question comes from the line of Patrick Dunley with Citi. Please proceed.
spk10: Hey, guys. Thank you for taking the questions. Elan, maybe first, probably Andy as well, just on the guidance, you know, pretty healthy life science number there, 16 to 18, X to COVID. Can you just talk about, you know, the growth drivers there, how much of that is, you know, maybe some of that backlog catch up, um, and also maybe just the pacing across the year. Obviously a lot goes into it between COVID and comps would be helpful just to get your perspective about the right way to think about that piece. And again, maybe some of the growth drivers that play into it.
spk05: Yeah. Hi Patrick. Thanks for the question. Andy here. So as we look at 23 revenue overall, let me, let me just break it down between the two business areas. Uh, So overall, I would say the strategic drivers of revenue growth remain consistent with our digital PCR platform, process Chrome continued growth in that platform area, and we're also going to benefit from new PCR products that were launched during the past year, and we've got some more coming during 23. I think our focus on biopharma penetration where we're largely underrepresented still, is also a very significant driver as we look to our growth in life science. And as a backdrop, we see life science funding broadly being positive and in all regions of the world. And so that's our general story on life science. As I look to the clinical business, Really, it's a continued growth of quality controls, continued share gains in immunohematology business. We've had some recent wins there, and we've got a growing demand pipeline. I would say also continued growth in Asia-Pac. and in particular kind of recovery in China more in the second half of 2023. Backlog reduction will be a feature in more the first half of the year. You know, and I think it was mentioned in our script that, you know, clinical has probably got the larger of the backlog challenge as we enter 23, but we have a really clear line of sight now. Q4 was still a bit challenging for us. And growth will kind of improve through the year for the business overall. And so I think that that's pretty much a wrap-up of how we're looking at 23.
spk10: Okay, that's very helpful. And then maybe to your point there in terms of early in the year, a little bit of the supply chain, a little bit of China, Can you just talk about the impact you saw in 4Q? You know, it seemed like the diagnostics piece clearly, you know, some headwinds, both from shipment delays and probably China. So maybe just talk through, I guess, what you saw there in terms of the impact and then the expectation, how much of this lingers into 1Q, you know, particularly maybe the China piece and what the right way to think about that is.
spk05: Yeah. You know, as we've mentioned before, the ability to overcome the supply chain constraints in a lifetime is much easier than the clinical side of the business, and that did persist for us through Q4. And then, you know, in Q4 in China with the change in government policy, that kind of basically represented both supply chain challenge as well as some demand drop-off. So China didn't really perform quite as expected for us in Q4. As we go into Q1, really our focus is on production, the improvement in volume on our instrument platforms to meet the backlog burndown and growing demand. And so it's less a component issue for us now on the clinical business. It is much more ramping the volume of production as we go, and we believe that's a first-half phenomena for us.
spk10: Okay, and if I can sneak one more in for Elam, maybe on the margin piece, you know, nice numbers here this year, thinking about 23, and then, you know, just the path, continued path to some of the targets you laid out at the analyst day last year. Can you just talk about, I guess, the key levers you have in 23? And then, you know, similarly, as we think about that EBITDA moving towards, I think it was a 28% number in 2025, you know, those levers that are still left to pull. I know some of the restructuring probably comes into play this year, but it would be helpful just to talk about the moving pieces this year and then, again, the confidence as we work our way towards that 28% number.
spk04: Sure. Thank you, Patrick. I appreciate the question. So, you know, if you look at the challenges that, you know, we experienced in 2022 and we think about 2023 specifically around supply chain constraints and the impact on, you know, elevated cost of raw materials specifically and higher logistics costs. So, as Andy mentioned earlier, we believe it's going to continue to improve. And that's part of our thinking in terms of, if you think about the gross margin, the improvement of gross margins throughout 2023, specifically in the second half of it. And then when you think about the other internal initiatives that we have in terms of productivity and efficiencies, in terms of the restructuring that we completed, and the move to Singapore that is in the final phases of additional manufacturing footprint. So all these initiatives will also contribute towards the achievement of the 2025 goals. And that's kind of what gives us the confidence level that the challenges that we went through in 2022 are more transitory, will continue to some extent into 2023. But it does not change our thinking about the 2025 model and the targets that we laid out back in the investor day. And obviously, that comes on top of all the top-line kind of growth drivers that, you know, in terms of, you know, that you're aware of. Right. Thank you, guys. I appreciate it.
spk07: Thank you. The next question comes from the line of Dan Leonard with Credit Suisse. Please proceed.
spk08: Hello. Thank you for taking the questions. My first question on the 2023 sales guidance, I guess, how important are those second half product launches you mentioned, the continuum and the second generation single cell instrument? How important are they to the 2023 sales outlook or are these more 2024 drivers?
spk05: Yeah, thanks, Dan. They're not a material contributor in 23. This is really staging our 24 revenue ambitions there so that introductions to the market but no material contribution understood and Andy possibly you can give an update on the Singapore manufacturing transition yeah happy to do so the plan is up and running in Singapore across all the product lines We're very pleased with the plant coming up to speed. I would say that the other key consideration here is that we still have our French plants operating and that wasn't our initial plan at this point in time, but we've kept them open because of the backorder reduction challenges that we have and so we're keeping plants open through the first half to the end of Q2 and then we'll finally close those plants and continue to grow capacity in the Singapore facilities. So at this point all has moved well, we've just had some kind of small diversions I would say in the past year.
spk08: Understood. And my final question, this might be related. Alon, I think you mentioned it would take eight quarters to normalize inventory. Why would it take so long? And is there any opportunity to normalize sooner?
spk04: So, you know, generally speaking, Dan, first of all, you know, 2023, you know, we plan to have a lower inventory level than 2022, just as, you know, the target that we set to ourselves. Some of the procurement or the procured raw material was done for instruments and components that will last longer than the next four quarters. And on purpose, we wanted to have some elevated level of raw material. And I do not see any risk of any write-offs for those since these are all for instrument buildup. So that was kind of part of our thinking in terms of the long-term plan. That's the reason that it will take probably eight quarters to normalize. As you can imagine, despite the fact that component availability became kind of, or it eased in terms of availability, but
spk05: it's not yet back to kind of a normalized level, and we still have some challenges there, and maybe Andy, you want to... Yeah, just this kind of a carry-forward effect from keeping the clinical plants open on two sides of the world as well for, you know, two to three quarters longer than anticipated, just some double down on inventory that we will then have to also burn through. So that's another contributory factor. Got it. Thank you.
spk08: Thank you, Dan.
spk07: Thank you. The next question comes from the line of Brandon Couillard with Jefferies. Please proceed.
spk09: Hey, thanks. Good afternoon, guys. Just a question on the four-year growth outlook, so just to make sure I got this right. So we take out kind of the COVID headwind, assume that goes to zero. You're talking about core growth. you know, in the double digits, I think you said 10% to 11% for the year, which is ahead of your sort of LRP that you laid out at the end of the day. You were talking about level of confidence in that level of growth and, you know, where in the portfolio you may have been a little more, you know, conservative in terms of your expectations.
spk05: So Sandy here, you broke up a little bit at the end there, so sorry, but... I mean, we have a fairly diligent process for building our plans for the year. Bottoms up by region, by portfolio or area. But the macro trends for us seem pretty robust on a fully global basis. Portfolio areas of growth that we've highlighted before are very consistently performing. I think 22 didn't quite, you know, we didn't quite reach our initial growth expectations, fully realized growth expectations. So you've got a little bit of a comp benefit there too and a little bit of benefit coming through from some elevated back order that we're taking into 23. So when we look at growth aspirations, which portions of the portfolio we expect to continue to go. We've got new product contribution, both from products launched within 22 and some new ones in particular areas of the portfolio. This year, we feel we've got a good growth trajectory for the business going forward.
spk09: Got it. Then on the digital PCR business, any changes in the competitive landscape that you're seeing in the market? I know Roche has launched their system. And then any kind of updated stats on that segment that you could share with us in terms of the instrument versus consumable mix, where that stands today, and maybe the in-market mix, maybe between biopharma, diagnostics, and just research, so what that looks like now?
spk00: Yeah, this is Simon. As we think about the digital PCR business overall, I'll say we're pretty pleased with the growth trajectory that we saw throughout 2022. We're pleased with the new product introductions and compound that with the burndown that we've started to see in the order backlog. We feel good that we've got some momentum as we come into 2023. And we talked previously about the market dynamics. Yeah, there's emerging competition, and we see it as a double-edged sword. It's expanding the addressable opportunity, but it's also something that we take very seriously. And as some of the earlier comments have mentioned, we're excited about the QX600 launch and the initial update that we're seeing with that. And when you blend the capabilities of that platform with the assay capabilities we've secured access to with Nupro, We believe we're going to be able to access segments of the market in a way that we weren't always able to do when we can be best in class in terms of performance. So we think we've got a lot of momentum and we also continue to feel very good about the mix between instruments and consumables as we head into 2023. And we see a lot of data points out in the market as well. And I think from our viewpoint, that's just really corroborated how good we felt about the performance in 22, and how particularly bullish we are coming into 2023.
spk09: Okay, Simon, while I've got you, on the Nupro licensing, the oncology content for DD-PCR, what's the timeline for commercialization of that? And then you've also had a couple of other partnership announcements recently. Well, with Cytec on the Starbrite flow cytometry dyes, there's another one with Element Bioscience for RNA library prep kits. Are any of those material in terms of revenue contributors in 2023? Is this part of a broader strategy to monetize more of the content you have in the portfolio through partnerships?
spk00: I wouldn't think about any of those as being material in 2023. I think we're going to have a pretty significant emphasis on assay development around new probe in 23. I mean, we've already got a lot of oncology content in the digital PCR franchise. It generates a lot of revenue for us already. And I think that's going to be a meaningful extension over time from 2024 onwards. Similarly, with the SciTech agreement that you mentioned, you know, we've got best in class performing dyes there with Starbright. And in addition to pushing direct portfolio. We're certainly wide open to partnerships there, and we think the partnership with SciTech is going to serve us well over time, but again, not meaningful in 2023.
spk09: Okay, last one, Alon. Did you mention a $5 to $10 million one-time revenue benefit in the fourth quarter? And what's the operating impact of that at the operating income line?
spk04: So, Brandon, it's, you know, on average kind of the gross margin, you know, benefit. So, it's not anything, you know, higher or lower. It's blended average for the gross margin. And it is a one-time for the fourth quarter between $5 million and $10 million, as I mentioned. Thank you very much. Thank you, Brandon.
spk07: Thank you. The next question comes from the line of Jack Meehan with Nefron Research. Please proceed.
spk02: Thank you. Good afternoon. I wanted to start with M&A. For Norman, just based on what you're seeing now, and if you look out for 2023, do you think tuck-in deals are more or less likely than something more transformative? And either for you or Elon, just latest thoughts on balance sheet and, you know, willingness for using equity as part of a deal?
spk03: Yeah, so yeah, we're kind of encouraged by what we see for 2023. If you think about the, you know, rising interest rates have, I think, slowed other people down a little bit. We certainly see opportunities out there, whether they would be more tuck-in or or more transformational, I think that's certainly, I mean, we'll see what we manage to find. We would hope to do something a little larger. We've done a number of these smaller tuck-ins, especially these kind of technology additions to the portfolio. I think we're looking now for something with a top line and a bottom line.
spk04: And Jake, I would add in terms of the mix between equity and debt, our preference is, again, to try and maximize the debt capacity. And maybe even you can call it a little bit stretching it. Historically, we were discussing around 3x of gross leverage You know, we'll try to be even above that so long as we maintain our investment grade level. And that, you know, can provide us kind of a nice-sized opportunity or to target a nice-sized opportunity.
spk02: Great. And then, just one other question. ask you a little bit more about potential for backlog flush in 2023. So you talked about 50 million of elevated backlog. And I think I heard you say, you think you can capture 30 million of that. It's just smaller than I would have expected. I, when I look at the inventory balance, you know, at your end up about 150 million year over year. Um, so I was just curious, like your line of sight into that and any color on, is it mostly life sciences?
spk04: Yes, so Jack, maybe one comment from my side, you know, maybe that is also related to the fact that it will take us about eight quarters and not four quarters, you know, to normalize that, you know, inventory level. Since we did procure on purpose, you know, in certain components, longer term kind of capacity. And probably that explains, you know, the reason for the higher elevated and you know, the kind of normalization and capturing kind of the order backlog or elevated order backlog during 2023. Okay.
spk02: And then a final one for you, Elon, and maybe also for Andy, the margin target of 19.5%. So off the new accounting in 2022, I think that's 80 bps of expansion year over year. You know, if I look over multiple years in the past, you've done, you know, over 100 a year, maybe even better than that. I know there's some dynamics with COVID and supply chain, but is there anything notable you would call out for why kind of the trend lines a little below the historical levels?
spk04: You know, it's a good question, Jack. I mean, some of, you know, the challenges obviously from 2022, you know, will continue, you know, in part of 2023. So that is still a headwind when you think about, you know, the higher cost of material that we have to flush through the inventory cycle. And that has an impact on gross margin, obviously. And, you know, it's a fall through to the operating margin. You know, I think that's kind of the main item that we have to kind of work through during 2023. And that's, again, the reason that we do believe that it's still transitory. And that's exactly the basis for our thinking in terms of Still, you know, confirming the 2025 target model because by that time, you know, we believe that, you know, those issues, you know, will no longer be there.
spk02: Sounds good. Thank you.
spk04: Thank you, Jack.
spk07: Thank you. Again, to ask a question, please press star 1. There are no additional questions at this time. I will now hand it back to the management team for closing remarks.
spk06: Thank you for joining today's call. We will be at the city conference in early March and hope to see some of you there. And as always, appreciate your interest. We look forward to connecting soon.
spk07: That concludes today's conference call. Thank you. You may now disconnect your lines.
Disclaimer